drugset / Trial / NCT05819892

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

NCT05819892

RandomizedSingle-groupOpen-labelTreatment

Summary

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied

Timeline

Start
2023-07-17
Primary completion
2027-03-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject Dostarlimab Monoclonal antibody Intravenous
Subject Paclitaxel Small molecule Intravenous

Indications